TIGIT (T cell immunoreceptor with Ig and ITIM domains) is a co-inhibitory receptor expressed on various immune cells, including T cells, NK cells, and dendritic cells. TIGIT interacts with different ligands, such as CD155 and CD112, which are highly expressed on cancer cells, leading to the suppression of immune responses. Recent studies have highlighted the importance of TIGIT in regulating immune cell function in the tumor microenvironment and its role as a potential therapeutic target, especially in the field of lung cancer. However, the role of TIGIT in cancer development and progression remains controversial, particularly regarding the relevance of its expression both in the tumor microenvironment and on tumor cells, with prognostic and predictive implications that remain to date essentially undisclosed. Here, we provide a review of the recent advances in TIGIT-blockade in lung cancer, and also insights on TIGIT relevance as an immunohistochemical biomarker and its possible theranostic implications.

TIGIT in Lung Cancer: Potential Theranostic Implications / C. Pescia, G. Pini, E. Olmeda, S. Ferrero, G. Lopez. - In: LIFE. - ISSN 2075-1729. - 13:4(2023 Apr 19), pp. 1050.1-1050.21. [10.3390/life13041050]

TIGIT in Lung Cancer: Potential Theranostic Implications

C. Pescia
Co-primo
;
G. Pini
Co-primo
;
E. Olmeda;S. Ferrero
Penultimo
;
G. Lopez
Ultimo
2023

Abstract

TIGIT (T cell immunoreceptor with Ig and ITIM domains) is a co-inhibitory receptor expressed on various immune cells, including T cells, NK cells, and dendritic cells. TIGIT interacts with different ligands, such as CD155 and CD112, which are highly expressed on cancer cells, leading to the suppression of immune responses. Recent studies have highlighted the importance of TIGIT in regulating immune cell function in the tumor microenvironment and its role as a potential therapeutic target, especially in the field of lung cancer. However, the role of TIGIT in cancer development and progression remains controversial, particularly regarding the relevance of its expression both in the tumor microenvironment and on tumor cells, with prognostic and predictive implications that remain to date essentially undisclosed. Here, we provide a review of the recent advances in TIGIT-blockade in lung cancer, and also insights on TIGIT relevance as an immunohistochemical biomarker and its possible theranostic implications.
PD-1; PD-L1; TIGIT; immune-checkpoint; lung cancer; predictive; prognostic; theranostic
Settore MED/08 - Anatomia Patologica
19-apr-2023
Article (author)
File in questo prodotto:
File Dimensione Formato  
life-13-01050-v2 (1).pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 589.26 kB
Formato Adobe PDF
589.26 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/999392
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact